VRDN Stock Overview
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Viridian Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$35.80 |
| 52 Week High | US$39.00 |
| 52 Week Low | US$9.47 |
| Beta | 1.01 |
| 1 Month Change | 30.37% |
| 3 Month Change | 88.62% |
| 1 Year Change | 79.09% |
| 3 Year Change | 186.00% |
| 5 Year Change | -56.61% |
| Change since IPO | -80.28% |
Recent News & Updates
Recent updates
Does Viridian Therapeutics (NASDAQ:VRDN) Have A Healthy Balance Sheet?
Jan 08
Viridian: Excellent Early Data, Strong Cash, Great Strategy, Large Market
Sep 09Viridian Therapeutics board compensation committee approves inducement grants
Sep 02An Intrinsic Calculation For Viridian Therapeutics, Inc. (NASDAQ:VRDN) Suggests It's 49% Undervalued
Aug 22Viridian Therapeutics Q2 2022 Earnings Preview
Aug 12Viridian Therapeutics gets a new COO
Jun 23Viridian Therapeutics (VRDN) Investor Presentation - Slideshow
Jun 08Viridian Therapeutics reports Q1 results
May 06Miragen: Viridian Therapeutics Acquisition Offers Good Speculative Entry Opportunity
Dec 08Shareholder Returns
| VRDN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.0% | -0.8% | 0.9% |
| 1Y | 79.1% | 3.9% | -10.9% |
Return vs Industry: VRDN exceeded the US Biotechs industry which returned 4.3% over the past year.
Return vs Market: VRDN exceeded the US Market which returned -9.6% over the past year.
Price Volatility
| VRDN volatility | |
|---|---|
| VRDN Average Weekly Movement | 9.0% |
| Biotechs Industry Average Movement | 12.0% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: VRDN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: VRDN's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 50 | Jonathan Violin | https://www.viridiantherapeutics.com |
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.
Viridian Therapeutics, Inc. Fundamentals Summary
| VRDN fundamental statistics | |
|---|---|
| Market Cap | US$1.44b |
| Earnings (TTM) | -US$113.03m |
| Revenue (TTM) | US$1.88m |
766.0x
P/S Ratio-12.7x
P/E RatioIs VRDN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VRDN income statement (TTM) | |
|---|---|
| Revenue | US$1.88m |
| Cost of Revenue | US$83.97m |
| Gross Profit | -US$82.09m |
| Other Expenses | US$30.95m |
| Earnings | -US$113.03m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.81 |
| Gross Margin | -4,364.17% |
| Net Profit Margin | -6,009.30% |
| Debt/Equity Ratio | 1.1% |
How did VRDN perform over the long term?
See historical performance and comparison